Stay updated on ARO-APOC3 in Mixed Dyslipidemia Clinical Trial

Sign up to get notified when there's something new on the ARO-APOC3 in Mixed Dyslipidemia Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARO-APOC3 in Mixed Dyslipidemia Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    Revision tag on the page updated from v3.5.3 to v3.5.4, indicating a metadata/version update. This change represents an internal versioning update and does not alter the study details or displayed information.
    Difference
    0.0%
    Check dated 2026-05-16T09:08:51.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    The page’s revision/version indicator was updated from v3.5.2 to v3.5.3, indicating a site update rather than a change to the ClinicalTrials.gov study details.
    Difference
    0.0%
    Check dated 2026-04-25T05:29:50.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Revision notes show the current release as Revision: v3.5.2 with dates 2026-04-14, 2026-04-10, and 2026-04. A prior Revision: v3.5.0 dated 2026-02-24, 2026-02-06, and 2026-02 has been removed.
    Difference
    0.2%
    Check dated 2026-04-18T03:50:25.000Z thumbnail image
  7. Check
    78 days ago
    Change Detected
    Summary
    Added Revision: v3.5.0 and removed Revision: v3.4.3 from the page.
    Difference
    0.0%
    Check dated 2026-03-20T05:19:06.000Z thumbnail image
  8. Check
    92 days ago
    Change Detected
    Summary
    Revision updated from v3.4.2 to v3.4.3 on the page.
    Difference
    0.0%
    Check dated 2026-03-05T19:47:13.000Z thumbnail image
  9. Check
    99 days ago
    Change Detected
    Summary
    Results were posted on 2026-02-24 and the study record was updated to reflect the new title 'Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia (MUIR)' with expanded design details and endpoints.
    Difference
    5%
    Check dated 2026-02-26T14:41:23.000Z thumbnail image

Stay in the know with updates to ARO-APOC3 in Mixed Dyslipidemia Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARO-APOC3 in Mixed Dyslipidemia Clinical Trial page.